News

ASH 2025: Milder chemo works for rare, aggressive lymphoma

A routine blood test could help predict who benefits most from CAR T-cell therapy

Novel AI technique able to distinguish between progressive brain tumours and radiation necrosis

Study finds childhood leukaemia aggressiveness depends on timing of genetic mutation

ASH 2025: Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially preventable

ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma

ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma

ASH 2025: Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukaemia patients eligible for intensive chemotherapy

ASH 2025: Chemo and radiation are comparable as pre-transplant conditioning for B-acute lymphoblastic leukaemia with no measurable residual disease

Triaptosis - an emerging paradigm in cancer therapeutics

Could altering the daily timing of immunotherapy improve survival in people with cancer?

Researchers identify target to overcome treatment resistance in preclinical models of KRAS-mutant cancers